IFOBT TF Only IFOBT Only TF BOTH EITHER P valuea
Positive patientsb 86(42.8) 93(46.3) 37(18.4) 44(21.9) 49(24.4) 130(64.7) 0.000
Sensitivityc              
All advanced adenomas and cancer(68) 38(55.9) 40(58.8) 13(19.1) 15(22.1) 25(36.8) 53(77.9) 0.006
Cancer(21) 12(57.1) 16(76.2) 2(9.5) 6(28.6) 10(47.6) 18(85.7) 0.040
Dukes A/B Cancer(9) 4(44.4) 6(66.7) 1(11.1) 3(33.3) 3(33.3) 7(77.8) 0.147
Dukes C/D Cancer(12) 8(66.7) 10(83.3) 1(8.3) 3(25.0) 7(58.3) 11(91.7) 0.142
Advanced adnomas(47) 26(55.3) 24(51.1) 11(23.4) 9(19.1) 15(31.9) 35(74.5) 0.052
Advanced adenoma ≥10 mm(36) 21(58.3) 16(44.4) 10(27.8) 5(13.9) 11(30.6) 26(72.2) 0.216
Advanced adenoma <10 mm(11)d 5(45.5) 8(72.7) 1(9.1) 4(36.4) 4(36.4) 9(81.8) 0.076
Specificitye              
All advanced adenomas and cancer(68) 48(63.9) 53(60.2) 24(82.0) 29(78.2) 24(82.0) 77(42.1) 0.005
Cancer(21) 74(58.9) 77(57.2) 35(80.6) 38(78.9) 39(78.3) 112(37.8) 0.005
Negative predictive valuef              
All advanced adenomas and cancer(68) 85(73.9) 80(74.1) 109(66.5) 104(66.2) 109(71.7) 56(78.9) 0.443
Cancer(21) 106(92.2) 103(95.4) 145(88.4) 142(90.4) 141(92.8) 68(95.8) 0.332
Positive predictive valueg              
All advanced adenomas and cancer(68) 38(44.2) 40(43.0) 13(35.1) 15(34.1) 25(51.0) 53(40.8) 0.619
Cancer(21) 12(14.0) 16(17.2) 2(5.4) 6(13.6) 10(20.4) 18(13.8) 0.982
Dukes A/B Cancer(9) 4(4.7) 6(6.5) 1(2.7) 3(6.8) 3(6.1) 7(5.4) 0.810
Dukes C/D Cancer(12) 8(9.3) 10(10.8) 1(2.7) 3(6.8) 7(14.3) 11(8.5) 0.831
Advanced adenomas(47) 26(30.2) 24(25.8) 11(29.7) 9(20.5) 15(30.6) 35(26.9) 0.597
Advanced adenoma≥10 mm(36) 21(24.4) 16(17.2) 10(27.0) 5(11.4) 11(22.4) 26(20.0) 0.441
Advanced adenoma<10 mm(11) 5(5.8) 8(8.6) 1(2.7) 4(9.1) 4(8.2) 9(6.9) 0.746
aTF combined with IFOBT (Either/or) vs IFOBT alone.
bNumbers in parenthesis are the rates calculated by number of positive patients divided by the number of total participants.
cSensitivity is the number of true positives relative to the number of persons with lesions.
d≥1 villous adenoma or adenoma with high-grade dysplasia and no adenomas ≥10mm
eSpecificity is the number of true negatives relative to the number of persons without lesions. Numbers presented are the number of false-positives per group.
fNPV is the number of true negatives relative to the number of persons with negative tests. Numbers presented are the number of true-negatives per group.
gPPV is the number of true positives relative to the number of total positive patients.
Table 4: Results of IFOBT and TF, either alone or combination, and subsequent colonoscopic findings in symptomatic population (201 participants), n(%).